Updates in the Treatment of HR+/HER2- Breast Cancer - Episode 15
Panelists discuss adverse events associated with antibody-drug conjugates (ADCs) that impact clinical decision-making and share strategies for managing these adverse events.
Video content above is prompted by the following: